千红制药(002550) - 2016 Q2 - 季度财报

Important Notes, Table of Contents and Definitions This section provides essential disclaimers, the report's table of contents, and key definitions for clarity - The company plans not to distribute cash dividends, bonus shares, or convert capital reserves into share capital for the first half of 2016[3][5] Company Profile This section provides fundamental information about the company, including its registration details and contact channels Company Overview This chapter provides the company's basic business registration information, including stock abbreviation "Qianhong Pharma", stock code "002550", and the company's full Chinese and English names and legal representative Company Basic Information | Item | Content | | :--- | :--- | | Stock Abbreviation | Qianhong Pharma | | Stock Code | 002550 | | Stock Exchange | Shenzhen Stock Exchange | | Chinese Name | Changzhou Qianhong Bio-pharma Co., Ltd. | | Legal Representative | Wang Yaofang | Contact Person and Information This chapter discloses the name and contact information of the company's board secretary, serving as the primary external communication channel Board Secretary Contact Information | Position | Name | Phone | Email | | :--- | :--- | :--- | :--- | | Board Secretary | Jiang Wenqun | 0519-85156003 | stock@qhsh.com.cn | Other Information This chapter describes the company's information disclosure media and registration changes. During the reporting period, the company's designated information disclosure newspapers were "Securities Times" and "Shanghai Securities News", and it completed the "three-in-one" change for business registration information - The company's designated information disclosure newspapers are "Securities Times" and "Shanghai Securities News", and the designated website is Juchao Information Network (http://www.cninfo.com.cn)[16](index=16&type=chunk) - During the reporting period, the company completed the "three-in-one" change for business registration information, unifying the new registration number, tax registration number, and organization code to 91320400748726864T[17] Summary of Accounting Data and Financial Indicators This section presents a concise overview of the company's key financial performance and position during the reporting period Key Accounting Data and Financial Indicators During the reporting period, the company achieved operating revenue of 362 million CNY, a year-on-year increase of 9.50%; net profit attributable to shareholders of listed company was 143 million CNY, a year-on-year increase of 7.29%. Net cash flow from operating activities decreased by 8.12% year-on-year Key Financial Data for H1 2016 | Indicator | Current Period (CNY) | Prior Year Period (CNY) | YoY Change | | :--- | :--- | :--- | :--- | | Operating Revenue | 362,339,737.55 | 330,909,032.54 | 9.50% | | Net Profit Attributable to Shareholders of Listed Company | 142,851,942.06 | 133,143,671.57 | 7.29% | | Net Profit Attributable to Shareholders of Listed Company (Excluding Non-recurring Gains/Losses) | 95,428,731.50 | 94,296,433.99 | 1.20% | | Net Cash Flow from Operating Activities | 160,916,492.13 | 175,139,448.67 | -8.12% | | Basic Earnings Per Share (CNY/share) | 0.1116 | 0.1040 | 7.31% | | Weighted Average Return on Net Assets | 6.13% | 6.15% | -0.02% | | Total Assets (CNY) | 2,845,714,250.45 | 2,833,137,726.31 | 0.44% | | Net Assets Attributable to Shareholders of Listed Company (CNY) | 2,321,038,424.02 | 2,274,186,481.96 | 2.06% | Non-recurring Gains and Losses Items and Amounts During the reporting period, the company's total non-recurring gains and losses amounted to 47.42 million CNY. The main contribution came from wealth management income from bank wealth management products and trust products, totaling 55.96 million CNY Non-recurring Gains and Losses Items | Item | Amount (CNY) | Explanation | | :--- | :--- | :--- | | Other gains and losses items conforming to the definition of non-recurring gains and losses | 55,959,790.90 | Includes income from bank wealth management products and trust products | | Government grants recognized in current profit or loss | 686,796.43 | - | | Gains or losses on disposal of non-current assets | -434,837.41 | - | | Less: Income tax impact | 8,525,308.06 | - | | Less: Impact of minority interests (after tax) | 273,930.15 | - | | Total | 47,423,210.56 | -- | Board of Directors' Report This section outlines the company's operational performance and strategic initiatives during the reporting period Business Overview During the reporting period, facing pressure from drug tender price reductions, the company maintained stable and healthy economic development by expanding markets, enriching product structure, improving R&D platforms, and advancing fundraising projects. Key initiatives included acquiring Innosenkang to fill the gap in small molecule drug R&D and new plant construction passing new GMP acceptance - The company maintained continuous, stable, and healthy economic development by expanding sales markets for key products and mitigating the downward pressure on drug tender prices[28] - The company obtained approval for enoxaparin sodium and dalteparin sodium APIs and preparations, enriching its product structure and creating new economic growth points. Enoxaparin sodium injection has been launched and is generating sales[28] - The company completed the acquisition of 55% equity in Changzhou Innosenkang Biomedical Technology Co., Ltd., filling the technical gap in small molecule drug R&D and complementing the existing large molecule R&D platform[29] - The company's new plant construction project in Changzhou Biomedical Industrial Park fully passed new GMP acceptance, and fundraising projects are largely complete, providing assurance for industrial transformation and upgrading[30] Analysis of Main Business During the reporting period, the company's operating revenue increased by 9.50%, mainly due to higher API sales; operating costs rose by 17.74% due to increased product sales and raw material prices. Financial expenses decreased by 24.71% due to increased wealth management income. Net cash flow from operating activities decreased by 8.12%, primarily due to the return of some project deposits Key Financial Data YoY Changes | Item | Current Period (CNY) | Prior Year Period (CNY) | YoY Change | Main Reason | | :--- | :--- | :--- | :--- | :--- | | Operating Revenue | 362,339,737.55 | 330,909,032.54 | 9.50% | Increased API sales | | Operating Cost | 133,814,908.24 | 113,651,169.02 | 17.74% | Increased product sales and raw material prices | | Financial Expenses | -53,279,145.83 | -42,721,270.54 | -24.71% | Increased wealth management income | | Net Cash Flow from Operating Activities | 160,916,492.13 | 175,139,448.67 | -8.12% | Return of some project deposits | | Net Cash Flow from Investing Activities | -66,846,282.54 | -218,372,770.22 | 69.39% | Maturity of some wealth management products | | Net Cash Flow from Financing Activities | -61,389,883.63 | 96,123,165.97 | -163.87% | Repayment of some bank loans | Main Business Composition The company's main business is biopharmaceuticals, with a gross profit margin of 63.14%, a year-on-year decrease of 2.60%. By product, API series revenue grew by 24.97%, while pharmaceutical preparations series only grew by 0.67%. By region, international revenue grew by 22.27%, significantly higher than the 4.08% growth in domestic regions Main Business Composition | Category | Operating Revenue (CNY) | Operating Cost (CNY) | Gross Profit Margin | YoY Change in Operating Revenue | YoY Change in Operating Cost | YoY Change in Gross Profit Margin | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | By Product | | | | | | | | API Series | 150,351,496.44 | 95,315,881.94 | 36.60% | 24.97% | 27.43% | -1.22% | | Pharmaceutical Preparations Series | 211,390,936.91 | 38,039,090.77 | 82.01% | 0.67% | 0.30% | 0.07% | | By Region | | | | | | | | Domestic Region | 241,229,340.13 | 54,987,774.03 | 77.21% | 4.08% | 10.80% | -1.38% | | International Region | 120,513,093.22 | 78,367,198.68 | 34.97% | 22.27% | 23.30% | -0.54% | Analysis of Core Competencies During the reporting period, the company's core competencies did not undergo significant changes compared to the annual report - The company's core competencies did not undergo significant changes during the reporting period[37] Analysis of Investment Status During this reporting period, the company made significant external equity investments, acquiring 55% of Changzhou Innosenkang Biomedical Technology Co., Ltd. for 16.5 million CNY. Concurrently, the company actively utilized idle self-owned and raised funds for entrusted wealth management, involving substantial amounts. The use of raised funds also progressed as planned, primarily for capacity expansion and R&D center construction External Equity Investments During the reporting period, the company's external investment amounted to 16.5 million CNY, used to acquire 55% equity in Changzhou Innosenkang Biomedical Technology Co., Ltd. to strengthen its biopharmaceutical R&D capabilities External Investment Details | Investee Company Name | Main Business | Investment Amount (CNY) | Equity Ratio in Investee Company | | :--- | :--- | :--- | :--- | | Changzhou Innosenkang Biomedical Technology Co., Ltd. | R&D of biopharmaceuticals, technical services, technical consulting, and technology transfer | 16,500,000.00 | 55.00% | Entrusted Wealth Management, Derivative Investments, and Entrusted Loans The company utilized idle self-owned funds and raised funds for large-scale entrusted wealth management, primarily investing in trust products and bank principal-protected wealth management products, totaling 1.49 billion CNY, with a realized profit of 33.18 million CNY during the reporting period - The company used idle self-owned funds and raised funds for entrusted wealth management, totaling 1.48992 billion CNY, with actual profit/loss of 33.1768 million CNY during the reporting period[44] - Entrusted wealth management funds originated from the company's idle self-owned funds and raised funds, of which 269.92 million CNY were raised funds[44] Use of Raised Funds As of the end of the reporting period, the company's total raised funds amounted to 1.215 billion CNY, with cumulative investment of 1.097 billion CNY, accounting for 90.3% of the total. Funds were primarily used for expansion projects of heparin, kallidinogenase, etc., joint research institute construction, and supplementing working capital. Some projects were delayed until March 31, 2016, due to changes in implementation locations, and are now largely complete Overall Use of Raised Funds (CNY 10,000) | Item | Amount | | :--- | :--- | | Total Raised Funds | 121,481.91 | | Total Raised Funds Invested in Current Period | 27,870.82 | | Total Raised Funds Cumulatively Invested | 109,744.42 | | Total Raised Funds with Changed Purpose (Cumulative) | 13,683 | | Proportion of Total Raised Funds with Changed Purpose (Cumulative) | 11.26% | - As of June 30, 2016, the company cumulatively used 1.097 billion CNY in raised funds, including 727 million CNY invested in fundraising projects, 20 million CNY for acquiring Innosenkang equity, 232 million CNY for repaying bank loans, and 119 million CNY for permanently supplementing working capital[51] - The completion deadline for the pharmaceutical preparation parts of multiple fundraising projects was adjusted from September 30, 2015, to March 31, 2016, due to changes in implementation locations. As of the end of the reporting period, the pharmaceutical preparation varieties in the new plant area have obtained GMP certificates, and five fundraising projects are largely complete[55] Analysis of Major Subsidiaries and Associates During the reporting period, the company's major subsidiaries were mostly in the investment or development stage and had not yet achieved profitability. Among them, Jiangsu Zhonghong Bioengineering Innovation Research Institute Co., Ltd. had a net loss of 0.57 million CNY, Hubei Runhong Biotechnology Co., Ltd. had a net loss of 1.74 million CNY, and the newly acquired Changzhou Innosenkang Biomedical Technology Co., Ltd. had a net loss of 2.51 million CNY Major Subsidiary Financial Performance (CNY) | Company Name | Operating Revenue | Operating Profit | Net Profit | | :--- | :--- | :--- | :--- | | Jiangsu Zhonghong Bioengineering Innovation Research Institute Co., Ltd. | 6,451,497.33 | -587,251.75 | -566,715.12 | | Jiangsu Jinghong Biomedical Technology Co., Ltd. | 0.00 | -408,470.69 | -408,470.69 | | Hubei Runhong Biotechnology Co., Ltd. | 0.00 | -1,496,767.33 | -1,744,580.19 | | Changzhou Innosenkang Biomedical Technology Co., Ltd. | 4,680.38 | -2,478,345.20 | -2,506,845.20 | Forecast of Operating Performance for January-September 2016 The company expects the net profit attributable to shareholders of the listed company for January-September 2016 to fluctuate between -20% and 20%. The main reasons for performance fluctuations include increased market investment due to new product promotion and potential temporary sales decline of the core product "Yikai" due to specification changes in some markets 2016 Q1-Q3 Performance Forecast | Item | Content | | :--- | :--- | | Net Profit Fluctuation Range | -20.00% to 20.00% | | Net Profit Fluctuation Range (CNY 10,000) | 16,106.46 to 24,159.68 | | Net Profit for Prior Year Period (CNY 10,000) | 20,133.07 | | Reasons for Performance Change | 1. Increased market investment for promoting new products like enoxaparin sodium injection;
2. Temporary sales decline of Yikai in some important markets due to specification changes;
3. Expected sales growth for other products. | Implementation of Profit Distribution Plan for the Reporting Period The company implemented its 2015 annual profit distribution plan, distributing a cash dividend of CNY 1.5 (tax inclusive) per 10 shares based on a total share capital of 640 million shares, totaling 96 million CNY in cash. Concurrently, 10 bonus shares were issued per 10 shares from capital reserves, increasing the total share capital to 1.28 billion shares. The plan was completed on May 24, 2016 - 2015 annual profit distribution plan: CNY 1.5 cash dividend (tax inclusive) per 10 shares, and 10 bonus shares per 10 shares from capital reserves[69] - After distribution, the company's total share capital increased from 640 million shares to 1.28 billion shares, and the distribution plan was completed on May 24, 2016[69][70] Proposed Profit Distribution or Capital Reserve to Share Capital Conversion Plan for the Reporting Period The company plans not to distribute profits for the first half of 2016, meaning no cash dividends, no bonus shares, and no conversion of capital reserves into share capital - The company plans not to distribute cash dividends, bonus shares, or convert capital reserves into share capital for the half-year period[72] Significant Matters This section details significant events and transactions that occurred during the reporting period Asset Transactions During the reporting period, the company acquired 55% equity in Changzhou Innosenkang Biomedical Technology Co., Ltd. for 16.5 million CNY. This acquisition aims to enhance the company's small molecule chemical drug innovation R&D platform, complementing the large molecule R&D platform of its subsidiary Zhonghong Research Institute, thereby improving overall R&D capabilities Acquisition of Assets | Acquired Asset | Transaction Price (CNY 10,000) | Progress | Impact on Company Operations | | :--- | :--- | :--- | :--- | | 55% Innosenkang Equity | 1,650 | Asset ownership has been fully transferred | Enhances the company's small molecule chemical drug innovation R&D platform, complementing and promoting the large molecule R&D platform. | Commitments Made by the Company or Shareholders Holding 5% or More of Shares During or Prior to the Reporting Period and Continuing into the Reporting Period The company's controlling shareholder Wang Yaofang and shareholders holding 5% or more, such as Zhao Gang, are fulfilling their commitments to avoid horizontal competition made during the initial public offering. Additionally, Wang Yaofang and Zhao Gang committed to an additional 3-year lock-up period for part of their shares, extending until February 24, 2017 - Controlling shareholder Wang Yaofang and Zhao Gang committed not to directly or indirectly engage in any business that constitutes horizontal competition with the company; this commitment is permanent and is currently being fulfilled normally[95] - Wang Yaofang and Zhao Gang separately committed to an additional 3-year lock-up period for 230 million shares and 102 million shares respectively, with the lock-up period extending until February 24, 2017; these commitments are currently being fulfilled normally[95][96] Explanation of Other Significant Matters During the reporting period, the company made several significant advancements: completing the acquisition of 55% equity in Innosenkang and planning to acquire an additional 10%; obtaining drug registration approvals for dalteparin sodium and its injection; and securing GMP certificates for enoxaparin API and various preparations (including tablets, capsules, etc.), providing assurance for expanding production scale - Completed the acquisition of 55% equity in Changzhou Innosenkang and plans to continue acquiring the remaining 10% state-owned equity to fill the gap in small molecule drug R&D[99] - Obtained drug registration approvals for dalteparin sodium and its injection[99] - Obtained GMP certificates for enoxaparin API, small volume injections, lyophilized powder injections, tablets, hard capsules, and other dosage forms, providing assurance for expanding production[99] Share Changes and Shareholder Information This section details changes in the company's share capital and information regarding its shareholders Share Change Information During the reporting period, due to the implementation of the 2015 annual equity distribution plan of "10 bonus shares for every 10 shares", the company's total share capital increased from 640 million shares to 1.28 billion shares. Restricted and unrestricted shares increased proportionally Share Change Comparison | Share Type | Before This Change (Shares) | After This Change (Shares) | | :--- | :--- | :--- | | Restricted Shares | 233,712,572 | 466,441,142 | | Unrestricted Shares | 406,287,428 | 813,558,858 | | Total Shares | 640,000,000 | 1,280,000,000 | - The main reason for the share change was the implementation of the 2015 annual equity distribution plan: 10 bonus shares for every 10 shares from capital reserves[104] Number of Shareholders and Shareholding Information As of the end of the reporting period, the company had a total of 54,793 common shareholders. The top two shareholders are company executives Wang Yaofang and Zhao Gang, holding 22.80% and 11.40% respectively, indicating a relatively concentrated equity structure - As of the end of the reporting period, the company had a total of 54,793 common shareholders[113] Top Ten Shareholders' Shareholding (As of End of Reporting Period) | Shareholder Name | Shareholder Nature | Shareholding Ratio | Number of Shares Held (Shares) | | :--- | :--- | :--- | :--- | | Wang Yaofang | Domestic Natural Person | 22.80% | 291,888,000 | | Zhao Gang | Domestic Natural Person | 11.40% | 145,944,000 | | Jiang Jianping | Domestic Natural Person | 3.80% | 48,648,000 | | Haitong Securities Co., Ltd. | State-owned Legal Person | 3.26% | 41,781,115 | | Industrial and Commercial Bank of China - GF Jufeng Mixed Securities Investment Fund | State-owned Legal Person | 2.70% | 34,500,000 | Changes in Controlling Shareholder or Actual Controller During the reporting period, there were no changes in the company's controlling shareholder or actual controller - The company's controlling shareholder and actual controller did not change during the reporting period[116] Information on Preferred Shares This section confirms the absence of preferred shares in the company's capital structure during the reporting period - The company had no preferred shares during the reporting period[119] Information on Directors, Supervisors, and Senior Management This section provides details on the shareholding and changes of the company's directors, supervisors, and senior management Shareholding Changes of Directors, Supervisors, and Senior Management During the reporting period, the shareholdings of the company's directors, supervisors, and senior management increased proportionally due to the implementation of the capital reserve to share capital conversion plan of "10 bonus shares for every 10 shares", with the total number of shares held at period-end doubling compared to the beginning of the period - Shareholding changes of directors, supervisors, and senior management primarily resulted from the capital reserve to share capital conversion; the number of shares increased in this period equals the initial shareholding, doubling the total shares held at period-end[121] Major D&O Shareholding Changes (Shares) | Name | Position | Shares Held at Beginning of Period | Shares Increased in Current Period | Shares Held at End of Period | | :--- | :--- | :--- | :--- | :--- | | Wang Yaofang | Chairman | 145,944,000 | 145,944,000 | 291,888,000 | | Zhao Gang | Vice Chairman, General Manager | 72,972,000 | 72,972,000 | 145,944,000 | | Jiang Jianping | Chairman of Supervisory Board | 24,324,000 | 24,324,000 | 48,648,000 | Changes in Directors, Supervisors, and Senior Management During the reporting period, there were no changes in the company's directors, supervisors, and senior management - The company's directors, supervisors, and senior management did not change during the reporting period[122] Financial Report This section presents the company's financial statements and related notes Audit Report The company's 2016 half-year financial report was not audited - The company's half-year financial report was not audited[125] Financial Statements This section provides the company's consolidated and parent company balance sheets, income statements, cash flow statements, and statements of changes in owners' equity as of June 30, 2016. The data shows total assets of 2.846 billion CNY, net assets attributable to parent company of 2.321 billion CNY, and net profit attributable to parent company of 143 million CNY for the first half of the year Consolidated Balance Sheet As of June 30, 2016, the company's total assets were 2.846 billion CNY, a slight increase of 0.44% from the beginning of the period. Current assets totaled 2.06 billion CNY, primarily consisting of other current assets (wealth management products) of 1.491 billion CNY. Total liabilities were 502 million CNY, and total owners' equity attributable to the parent company was 2.321 billion CNY Consolidated Balance Sheet Key Items (CNY) | Item | Period-End Balance | Period-Beginning Balance | | :--- | :--- | :--- | | Total Assets | 2,845,714,250.45 | 2,833,137,726.31 | | Total Current Assets | 2,060,200,669.40 | 2,176,180,388.64 | | Total Non-Current Assets | 785,513,581.05 | 656,957,337.67 | | Total Liabilities | 502,243,855.11 | 538,670,103.54 | | Total Owners' Equity Attributable to Parent Company | 2,321,038,424.02 | 2,274,186,481.96 | Consolidated Income Statement In the first half of 2016, the company achieved total operating revenue of 362 million CNY, a year-on-year increase of 9.50%. Operating profit was 169 million CNY, an 8.3% increase year-on-year. Net profit attributable to parent company owners was 143 million CNY, a 7.29% increase year-on-year Consolidated Income Statement Key Items (CNY) | Item | Current Period Amount | Prior Period Amount | | :--- | :--- | :--- | | I. Total Operating Revenue | 362,339,737.55 | 330,909,032.54 | | II. Total Operating Costs | 193,504,569.78 | 175,109,085.64 | | III. Operating Profit | 168,846,970.88 | 155,898,288.25 | | IV. Total Profit | 169,097,825.64 | 158,105,886.63 | | Net Profit Attributable to Parent Company Owners | 142,851,942.06 | 133,143,671.57 | Consolidated Cash Flow Statement In the first half of 2016, the company's net cash flow from operating activities was 161 million CNY, a year-on-year decrease of 8.12%. Net cash outflow from investing activities was 67 million CNY, mainly due to the purchase of wealth management products. Net cash outflow from financing activities was 61 million CNY, primarily for repaying bank loans. Cash and cash equivalents balance at period-end was 201 million CNY Consolidated Cash Flow Statement Key Items (CNY) | Item | Current Period Amount | Prior Period Amount | | :--- | :--- | :--- | | Net Cash Flow from Operating Activities | 160,916,492.13 | 175,139,448.67 | | Net Cash Flow from Investing Activities | -66,846,282.54 | -218,372,770.22 | | Net Cash Flow from Financing Activities | -61,389,883.63 | 96,123,165.97 | | Net Increase in Cash and Cash Equivalents | 34,813,364.92 | 54,357,544.23 | Notes to Consolidated Financial Statements This chapter provides detailed explanations of key items in the consolidated financial statements. Key information includes: other current assets containing 1.491 billion CNY in wealth management products; construction in progress primarily for fundraising projects, with a period-end balance of 522 million CNY; goodwill of 10.57 million CNY newly added due to the acquisition of Innosenkang; and financial expenses of negative 53.28 million CNY, mainly benefiting from interest income from wealth management products - Other current assets at period-end amounted to 1.491 billion CNY, of which 1.49 billion CNY were wealth management products[293] - Construction in progress had a period-end book value of 522 million CNY, primarily for five fundraising projects and one over-raised project, with a period-end balance of 514 million CNY[331][332] - Goodwill of 10,571,490.60 CNY was newly added in this period due to the acquisition of Changzhou Innosenkang Biomedical Technology Co., Ltd.[345][467] - Financial expenses were -53,279,145.83 CNY, mainly comprising interest income of 59,698,254.71 CNY from wealth management products[433] Changes in Consolidation Scope During the reporting period, the company added "Changzhou Innosenkang Biomedical Technology Co., Ltd." as a new consolidated entity due to a non-common control business combination. The company acquired 55% of its equity for 16.5 million CNY in cash on January 26, 2016, and this acquisition resulted in 10.57 million CNY in goodwill - This period saw a non-common control business combination, with the acquisition of 55% equity in Changzhou Innosenkang Biomedical Technology Co., Ltd. for 16.5 million CNY in cash[466] Consolidation Cost and Goodwill (CNY) | Item | Amount | | :--- | :--- | | Total Consolidation Cost | 16,500,000.00 | | Less: Fair Value Share of Identifiable Net Assets Acquired | 5,928,509.40 | | Goodwill | 10,571,490.60 | Interests in Other Entities This chapter discloses the company's enterprise group structure. As of the end of the reporting period, the company owned 7 subsidiaries, including Hubei Runhong (100% held), Jiangsu Zhonghong (59% held), and the newly acquired Innosenkang (55% held). Important non-wholly owned subsidiaries Jiangsu Zhonghong and Jiangsu Jinghong were both in a loss-making state during this period Enterprise Group Composition | Subsidiary Name | Shareholding Ratio (Direct) | Acquisition Method | | :--- | :--- | :--- | | Hubei Runhong Biotechnology Co., Ltd. | 100.00% | Establishment | | Jiangsu Zhonghong Bioengineering Innovation Research Institute Co., Ltd. | 59.00% | Establishment | | Jiangsu Jinghong Biomedical Technology Co., Ltd. | 51.00% | Establishment | | Changzhou Innosenkang Biomedical Technology Co., Ltd. | 55.00% | Non-common control business combination | Supplementary Information This chapter provides supplementary financial information, including details of non-recurring gains and losses and return on net assets. During the reporting period, the company's total non-recurring gains and losses amounted to 47.42 million CNY, primarily from wealth management product income. The weighted average return on net assets attributable to common shareholders was 6.13%, and basic earnings per share was 0.1116 CNY/share - Current period non-recurring gains and losses totaled 47,423,210.56 CNY, with the main item being "other gains and losses items conforming to the definition of non-recurring gains and losses" (primarily wealth management income), amounting to 55,959,790.90 CNY[556] Return on Net Assets and Earnings Per Share | Profit for the Period | Weighted Average Return on Net Assets | Basic Earnings Per Share (CNY/share) | Diluted Earnings Per Share (CNY/share) | | :--- | :--- | :--- | :--- | | Net Profit Attributable to Common Shareholders | 6.13% | 0.1116 | 0.1116 | | Net Profit Attributable to Common Shareholders (Excluding Non-recurring Gains/Losses) | 4.10% | 0.0746 | 0.0746 | Reference Documents This section lists the official documents available for public inspection and verification of the report's contents - Reference documents include:
- Signed and sealed financial statements
- Original copies of all publicly disclosed documents and announcements during the reporting period
- Original text of the 2016 half-year report signed by the chairman[559]